Authors
Velieva I.A., Kulagina N.V.
Research Institute of Eye Diseases, Moscow
Abstract
Introduction. Panretinal laser photocoagulation (PRP) is an etiopathogenetically oriented highly effective method in the management of patients with proliferative diabetic retinopathy (PDR). However, in some cases, the progression of the disease is observed despite the PRP performed.
Purpose: to estimate the possible causes of PDR progression in the eyes with PRP performed.
Material and methods. The study included 37 patients (34 eyes) with signs of PDR progression in the setting of type 1 diabetes mellitus, despite prior PRP. All patients were interviewed, had their medical histories taken and underwent ophthalmologic examinations, as well as consultations with an internist and an endocrinologist. Possible causes of PDR progression despite prior PRP were assessed retrospectively.
Results. Based on the findings, patients with active proliferative diabetic retinopathy (PDR) in eyes previously treated with panretinal laser photocoagulation (PRP) can be divided into four groups according to the probable cause of disease progression and the treatment approach:
- Incomplete laser treatment — 11.76% of cases;
- Decompensation of the underlying disease — 17.65%;
- A combination of incomplete laser treatment and decompensation of the underlying disease — 58.82%;
- An individually aggressive course of diabetes mellitus (DM) resistant to the treatment and preventive measures used — 11.76% of cases.
When PRP was inadequate, additional sessions of retinal laser photocoagulation were performed. As indicated, baseline therapy was adjusted, along with measures to improve blood rheology and the lipid profile.
Conclusion. According to the results of this study, the main causes of PDR progression in eyes previously treated with PRP are an incomplete volume of laser treatment and decompensation of the underlying disease. These factors may also occur in combination. An individually aggressive course of DM despite the treatment measures used is another possible cause. Clinical recommendations have been formulated.
Keywords: panretinal laser photocoagulation, proliferative diabetic retinopathy.
References
1. Bol’shunov AV, editor. Voprosy lazernoi oftal’mologii. Moscow: Aprel’; 2013. (In Russ).
2. American Academy of Ophthalmology. Diabetic Retinopathy. San Francisco (CA): American Academy of Ophthalmology; 2017.
3. Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: The International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology. 2018; 125(10): 1608–1622. doi: 10.1016/j.ophtha.2018.04.007.
4. Wong TY, Cheung CMG, Larsen M, et al. Diabetic retinopathy. Nat Rev Dis Primers. 2016; 2: 16012. doi: 10.1038/nrdp.2016.12.
5. Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight. 2017; 2(14): e93751. doi: 10.1172/jci.insight.93751.
6. Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. 2018; 19(6): 1816. doi: 10.3390/ijms19061816.
7. Mansour SE, Browning DJ, Wong K, et al. The evolving treatment of diabetic retinopathy. Clin Ophthalmol. 2020; 14: 653–678. doi: 10.2147/OPTH.S236637.
8. Budzinskaya MV, Petrachkov DV, Savochkina OA, Arzhukhanov DD. On the issue of classification of diabetic retinopathy. Vestn Oftalmol. 2019;135(5 Pt 2): 272–277. (In Russ). doi: 10.17116/oftalma2019135052272.
9. Sdobnikova SV, Mirzabekova KA. Pathogenetic features and treatment methods of different stages of diabetic retinopathy. Vestn Oftalmol. 2013; 129(3): 54–57. (In Russ).
10. Weng CY. The expanding role of anti-VEGF in the management of diabetic retinopathy. Retinal Physician. 2020; 17: 34–36.
11. Zhao M, Sun Y, Jiang Y. Anti-VEGF therapy is not a magic bullet for diabetic retinopathy. Eye (Lond). 2020; 34(4): 609–610. doi: 10.1038/ s41433-019-0652-3.
12. Gagloev BV, Pozdeeva NA, Al-Darraji IOKh. Concentration of VEGF-A in the intraocular fluid of rats with alloxan model of diabetes mellitus. Vestn Oftalmol. 2021; 137(2): 12–17. (In Russ). doi: 10.17116/oftalma202113702112.
13. Hendrikse F, Yeo KT. Role of the vitreous body in diabetic retinopathy. Klin Monbl Augenheilkd. 1993; 203(5): 319–323. doi: 10.1055/s-2008-1045684.
14. Agarwal D, Gelman R, Ponce CP, et al. The vitreomacular interface in diabetic retinopathy. J Ophthalmol. 2015; 2015: 392983. doi: 10.1155/ 2015/392983.
15. Sdobnikova SV, Stoliarenko GE, Fedorov AA, Marchenko NR. On the role of the posterior hyaloid membrane in the pathogenesis of and surgery for proliferative diabetic retinopathy. Vestn Oftalmol. 1996; 112(4): 5–7. (In Russ).
16. Krasnov MM, Sdobnikova SV, Fedorov AA, Stoliarenko GE. Posterior hyaloid membrane as structural base of growth of neovascular tissue in proliferative diabetic retinopathy. Vestn Oftalmol. 1998; 114(3): 16–20. (In Russ).
17. Sdobnikova SV, Stoliarenko GE. Contribution of posterior hyaloid membrane to pathogenesis and transciliary surgery of proliferative diabetic retinopathy. Vestn Oftalmol. 1999; 115(1): 11–13. (In Russ).
18. Sebag J, Buzney SM, Belyea DA, et al. Posterior vitreous detachment following panretinal laser photocoagulation. Graefes Arch Clin Exp Ophthalmol. 1990; 228(1): 5–8. doi: 10.1007/BF02764282.
19. Starostina EG, Volodina MN. Rol’ komplaentnosti v vedenii bol’nykh diabetom. Russkii meditsinskii zhurnal. 2015; 23(8): 477–480. (In Russ).
20. Neroev VV, Zaitseva OV, Okhotsimskaya TD, et al. Laser multicolor ophthalmoscopy in complex diagnostics of severe proliferative diabetic retinopathy. Vestn Oftalmol. 2019; 135(2): 22–31. (In Russ). doi: 10.17116/oftalma201913502122.
21. Pavlov VG, Sidamonidze AL, Petrachkov DV. Current trends in diabetic retinopathy screening. Vestn Oftalmol. 2020; 136(4 Pt 2): 300–309. (In Russ). doi: 10.17116/ oftalma2020136042300.
22. Petrachkov DV, Budzinskaya MV, Baryshev KV. Current possibilities for visualizing the peripheral retina in diabetic retinopathy. Vestn Oftalmol. 2020; 136(4 Pt2): 272–278. (In Russ). doi: 10.17116/oftalma2020136042272.


